GEN Exclusives

More »

GEN News Highlights

More »
May 1, 2012

Dako, Genentech Ink Second Companion Diagnostic Partnership

  • Dako signed an agreement with Genentech to collaborate on FDA regulatory submissions of two Dako tests as companion diagnostics for Genentech’s trastuzumab emtansine (T-DM1), a candidate for advanced Her2-positive breast cancer. The submission would cover use of HercepTest™ and HER2 FISH pharmDx™ to identify patients who may be eligible for treatment with T-DM1.

    In March Roche, Genentech’s parent company, confirmed plans to file regulatory approval applications for T-DM1, an antibody-drug conjugate, to both FDA and the European authorities later this year. The decision came on the back of positive data from the first Phase III study evaluating the drug in the treatment of metastatic breast cancer (mBC). T-DM1 combines Roche’s Herceptin (trastuzumab) and ImmunoGen’s cancer-killing agent DM1 using ImmunoGen’s linker technology.

    Today's announcement from Dako and Genentech comes on the heels of another collaboration between the firms. Last December the companies decided to collaborate on the regulatory submissions of HercepTest and HER2 FISH pharmDx as companion diagnostics for Pertuzumab. Roche has submitted a BLA and MAA for people with previously untreated, Her2-positive metastatic breast cancer.

    Dako’s deal with Genentech is in line with its strategy to combine its strengths with pharmaceutical companies to grow its offering of companion diagnostic assays. The company has cancer companion diagnostic deals with several firms including Amgen, Bristol-Myers Squibb, and OSI Pharmaceuticals.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »